Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14625014 | 1.00 | GNPAT (0.51) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| SCHEMBL6558713 | 1.00 | GNPAT (0.51) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL27616755 | 0.97 | GNPAT (0.50) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| SCHEMBL3469298 | 0.82 | ECE1 (0.46) | GNPATCA2CA1 | |
| SCHEMBL3821101 | 0.82 | ECE1 (0.46) | GNPATCA2CA1 | |
| Water SCHEMBL31495128 | 0.80 | ECE1 (0.44) | GNPATCA2CA1 | |
| SCHEMBL22042308 | 0.80 | GNPAT (0.45) | GNPATTDP1SMN1; SMN2LMNAFOLH1 | |
| Hydroxyamine SCHEMBL631500 | 0.79 | CA2 (0.45) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| SCHEMBL633735 | 0.79 | CA2 (0.45) | GNPATCA2CA4TDP1SMN1; SMN2 | |
| SCHEMBL2916092 | 0.78 | CA2 (0.48) | CA2CA4TDP1SMN1; SMN2SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117597407-A | Silicone modified polyurea coating compositions | PPG工业俄亥俄公司 | 2024-02-23 | — | — | CN | claimed |
| CN-111165710-A | Bifidobacterium bifidum probiotic solid beverage with cell aging resistance | 任彦芬 | 2020-05-19 | — | — | CN | claimed |
| CN-103635501-A | Pavement marking composition system | 3M INNOVATIVE PROPERTIES CO | 2014-03-12 | — | — | CN | claimed |
| EP-3355885-B1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS INC (US) | 2026-02-25 | — | — | EP | disclosed |
| WO-2025216797-A1 | DOSING OF POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250250340-A1 | METHOD TO PURIFY AN ANTIBODY COMPOSITION | Dr Reddy’s Laboratories Ltd (IN) | 2025-08-07 | — | — | US | disclosed |
| US-12319940-B2 | Methods for purification of arylsulfatase A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-03 | — | — | US | disclosed |
| US-20250161468-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119979504-A | Process for purifying arylsulfatase A | 武田药品工业株式会社 | 2025-05-13 | — | — | CN | disclosed |
| EP-4545141-A2 | PURIFIED ARYLSULFATASE A AND COMPOSITIONS THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-04-30 | — | — | EP | disclosed |
| US-20250073320-A1 | PURIFIED ARYLSULFATASE A AND COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-03-06 | — | — | US | disclosed |
| CN-1630516-A | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents | UAB RESEARCH FOUNDATION (US) | 2005-06-22 | — | — | CN | disclosed |
| CN-1191288-C | Crosslinking process | 3M INNOVATIVE PROPERTIES CO (US) | 2005-03-02 | — | — | CN | disclosed |
| CN-1128170-C | Liquid pavement marking composation | MINNESOTA MINING & MFG (US) | 2003-11-19 | — | — | CN | disclosed |
| EP-1322616-A2 | QUINOLINE-(C=O)-(DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| CN-1413224-A | Crosslinking process | 3M INNOVATIVE PROPERTIES CO (US) | 2003-04-23 | — | — | CN | disclosed |
| WO-2002018341-A9 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYST PROD INC (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020052323-A1 | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents | MP BIOMEDICALS, LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002018341-A2 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| CN-1260808-A | Liquid pavement marking composation | MINNESOTA MINING & MFG (US) | 2000-07-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161468-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRL1 | GNPAT 476/4885CA2 2468/4885CA4 2919/4885 |
| US-20020052323-A1 | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents | CASP3, CASP1, BAX | GNPAT 4394/4885CA2 3187/4885CA4 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.